Rasmiena Aliki A, Barlow Christopher K, Stefanovic Nada, Huynh Kevin, Tan Ricardo, Sharma Arpeeta, Tull Dedreia, de Haan Judy B, Meikle Peter J
Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia; Department of Biochemistry and Molecular Biology, The University of Melbourne, Parkville, Australia.
Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
Atherosclerosis. 2015 Dec;243(2):598-608. doi: 10.1016/j.atherosclerosis.2015.10.096. Epub 2015 Oct 26.
We previously reported a negative association of circulating plasmalogens (phospholipids with proposed atheroprotective properties) with coronary artery disease. Plasmalogen modulation was previously demonstrated in animals but its effect on atherosclerosis was unknown. We assessed the effect of plasmalogen enrichment on atherosclerosis of murine models with differing levels of oxidative stress.
Six-week old ApoE- and ApoE/glutathione peroxidase-1 (GPx1)-deficient mice were fed a high-fat diet with/without 2% batyl alcohol (precursor to plasmalogen synthesis) for 12 weeks. Mass spectrometry analysis of lipids showed that batyl alcohol supplementation to ApoE- and ApoE/GPx1-deficient mice increased the total plasmalogen levels in both plasma and heart. Oxidation of plasmalogen in the treated mice was evident from increased level of plasmalogen oxidative by-product, sn-2 lysophospholipids. Atherosclerotic plaque in the aorta was reduced by 70% (P = 5.69E-07) and 69% (P = 2.00E-04) in treated ApoE- and ApoE/GPx1-deficient mice, respectively. A 40% reduction in plaque (P = 7.74E-03) was also seen in the aortic sinus of only the treated ApoE/GPx1-deficient mice. Only the treated ApoE/GPx1-deficient mice showed a decrease in VCAM-1 staining (-28%, P = 2.43E-02) in the aortic sinus and nitrotyrosine staining (-78%, P = 5.11E-06) in the aorta.
Plasmalogen enrichment via batyl alcohol supplementation attenuated atherosclerosis in ApoE- and ApoE/GPx1-deficient mice, with a greater effect in the latter group. Plasmalogen enrichment may represent a viable therapeutic strategy to prevent atherosclerosis and reduce cardiovascular disease risk, particularly under conditions of elevated oxidative stress and inflammation.
我们之前报道循环缩醛磷脂(具有动脉粥样硬化保护特性的磷脂)与冠状动脉疾病呈负相关。缩醛磷脂调节在动物实验中已有证实,但其对动脉粥样硬化的影响尚不清楚。我们评估了缩醛磷脂富集对不同氧化应激水平小鼠模型动脉粥样硬化的影响。
六周龄的载脂蛋白E(ApoE)缺陷小鼠和载脂蛋白E/谷胱甘肽过氧化物酶-1(GPx1)双缺陷小鼠,喂食含/不含2%鲨肝醇(缩醛磷脂合成前体)的高脂饮食12周。脂质的质谱分析显示,给ApoE缺陷小鼠和ApoE/GPx1双缺陷小鼠补充鲨肝醇可增加血浆和心脏中的总缩醛磷脂水平。从缩醛磷脂氧化副产物sn-2溶血磷脂水平升高可明显看出,处理组小鼠的缩醛磷脂发生了氧化。在接受处理的ApoE缺陷小鼠和ApoE/GPx1双缺陷小鼠中,主动脉粥样硬化斑块分别减少了70%(P = 5.69×10⁻⁷)和69%(P = 2.00×10⁻⁴)。仅在接受处理的ApoE/GPx1双缺陷小鼠的主动脉窦中,斑块也减少了40%(P = 7.74×10⁻³)。仅接受处理的ApoE/GPx1双缺陷小鼠的主动脉窦中血管细胞黏附分子-1(VCAM-1)染色减少了28%(P = 2.43×10⁻²),主动脉中硝基酪氨酸染色减少了78%(P = 5.11××10⁻⁶)。
通过补充鲨肝醇使缩醛磷脂富集可减轻ApoE缺陷小鼠和ApoE/GPx1双缺陷小鼠的动脉粥样硬化,对后一组的效果更明显。缩醛磷脂富集可能是预防动脉粥样硬化和降低心血管疾病风险的一种可行治疗策略,尤其是在氧化应激和炎症升高的情况下。